Grepafloxacin

Drug Profile

Grepafloxacin

Alternative Names: Grepafloxacin hydrochloride; Grepax; OPC 17116; Raxar; Vaxar; Vorzan

Latest Information Update: 26 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer GlaxoSmithKline; Otsuka Pharmaceutical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Acute exacerbations of chronic bronchitis; Bacterial infections; Community-acquired pneumonia; Gonococcal urethritis; Gonorrhoea
  • Discontinued Respiratory tract infections; Sinusitis; Urinary tract infections

Most Recent Events

  • 26 Feb 2008 Discontinued - Clinical-Phase-Unknown for Respiratory tract infections in China (PO)
  • 26 Feb 2008 Discontinued - Clinical-Phase-Unknown for Respiratory tract infections in Taiwan (PO)
  • 26 Feb 2008 Discontinued - Preregistration for Respiratory tract infections in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top